# Limitless X Holdings Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Limitless X Holdings Inc.). ## Overview Limitless X Holdings Inc. is a U.S.-based consumer products and brand licensing company centered on nutritional supplements and related wellness products. Its business has included manufacturing and distributing licensed products under agreements tied to brands controlled by its CEO, with recent disclosures showing a narrower focus on the NZT-48 supplement line after other licensed product lines were discontinued. ## Products & services • Nutritional supplements, including NZT-48 • Licensed consumer wellness products • Manufacturing and distribution under brand licenses • Royalty-based product commercialization agreements - **Nutritional supplements** (70%) — Dietary and wellness supplement products sold under the company's branded and licensed portfolio. - **Licensed consumer products** (20%) — Products manufactured and distributed under third-party or related-party brand licenses. - **Royalty and licensing arrangements** (10%) — Revenue-linked commercialization rights and royalty economics tied to licensed brands. - Nutritional supplements, including NZT-48 - Licensed consumer wellness products - Manufacturing and distribution under brand licenses - Royalty-based product commercialization agreements ## Customers The company sells to consumers seeking nutritional and wellness products, typically through branded consumer channels rather than enterprise customers. Its commercial model also depends on licensors and related-party brand owners, since product rights and royalty terms shape what can be manufactured and distributed. - **End consumers** (primary) — Buy supplements such as NZT-48 for personal wellness, convenience, and brand appeal. - **Brand licensors** (primary) — Provide product rights and receive royalties; they determine which products can be sold. - **Retail and distribution channels** (secondary) — Purchase or carry the company's consumer products to reach final shoppers. - Consumers buying nutritional supplements for wellness and lifestyle use - Retail or direct-to-consumer buyers of branded supplement products - License counterparties that control product brands and commercialization rights - Related-party brand owners tied to the CEO's product portfolio ## Geography The available filings do not disclose a meaningful country-by-country revenue split, so the business profile is best understood as U.S.-centric. As a U.S. reporting company, its operating, legal, and financing activities are anchored in the United States, while product sales may extend through consumer distribution channels not separately broken out in the excerpts. - United States is the primary operating and reporting base - No country-level revenue split was disclosed in the excerpts - Consumer product sales may be distributed through U.S. channels - Geographic concentration increases dependence on U.S. demand and regulation ## Strategy Recent disclosures suggest a strategy of narrowing the product portfolio and concentrating on the NZT-48 supplement line after discontinuing other licensed gummy products. The company also appears focused on simplifying its licensing structure and resolving related-party royalty balances, which can reduce operational complexity and improve control over the remaining product set. - **Focus on core supplement products** (short-term) — A narrower portfolio can improve execution, inventory control, and brand focus. - **Rationalize licensing and royalty structure** (short-term) — Lower complexity may reduce disputes, cash leakage, and related-party friction. - Concentrate on NZT-48 after discontinuing other licensed products - Simplify the licensing portfolio and reduce product-line complexity - Manage royalty obligations and related-party arrangements - Preserve commercialization rights for the remaining supplement line ## Risks The company faces concentration risk because its product set has been narrowed and its commercial rights depend on a small number of license agreements. It also has related-party exposure, royalty obligations, and a history of dividend waivers and offsets, which can complicate governance, cash flow, and financial reporting. As a consumer wellness business, it is also exposed to demand volatility, product acceptance risk, and regulatory scrutiny over supplement claims and manufacturing quality. - **Product concentration** [high] — The portfolio has been narrowed to NZT-48 and a limited set of remaining products. - **Related-party dependence** [high] — Key licenses and preferred stock holders are tied to the CEO or CEO-controlled entities. - **License and royalty risk** [high] — The company needs valid license rights to manufacture and distribute products. - **Consumer demand and regulatory risk** [medium] — Supplement sales depend on consumer acceptance and compliance with product rules. - Heavy dependence on a small number of supplement products - License termination or non-renewal could remove key commercialization rights - Related-party transactions increase governance and conflict risk - Royalty and dividend obligations can pressure liquidity - Supplement regulation and product claims can affect sales and compliance ## Accounting The most important accounting issues appear to be revenue recognition for product sales, royalty accruals, and the accounting treatment of related-party settlements and waivers. The company also has balance-sheet items tied to license terminations, returned inventory, and accrued dividends on preferred stock, which can materially affect reported liabilities, receivables, and equity. - **Revenue recognition for product sales** — Affects reported sales timing and net revenue - **Royalty accruals and license obligations** — Affects gross margin and accrued liabilities - **Inventory returns and license termination accounting** — Affects inventory, receivables, and settlement gains/losses - **Preferred stock dividend accruals and waivers** — Affects equity, liabilities, and related-party disclosures - Revenue recognition depends on when supplement sales are delivered and accepted - Royalty accruals affect cost of sales and liabilities - Returned inventory and license terminations can create receivables or offsets - Preferred stock dividend accruals and waivers affect equity and liabilities - Related-party settlements require careful disclosure and measurement --- *Last updated: 2026-04-28T20:23:03.326261+00:00*